Business
Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama
Eli Lilly and Company (NYSE: LLY) today announced plans to invest more than $6 billion in a new manufacturing facility in Huntsville, Alabama. This next-generation synthetic medicine active pharmaceutical ingredient (API) facility, the third of four new U.S. sites Lilly plans to announce, will produce small molecule synthetic and peptide medicines.
About this update from Eli Lilly And Company
[{"type":"text","content":"Huntsville site will focus on domestic production of small molecule synthetic and peptide medicines, including Lilly's oral GLP-1, orforglipron","length":147,"tagName":"p","attribs":{}},{"type":"text","content":"Company plans to create 3,450 manufacturing and construction jobs at Lilly's ninth U.S. manufacturing site announced since 2020 ","length":131,"tagName":"p","attribs":{}},{"type":"text","content":"INDIANAPOLIS, Dec. 9, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced plans to invest more than $6 billion in a new manufacturing facility in Huntsville, Alabama. This next-generation synthetic medicine active pharmaceutical ingredient (API) facility, the third of four new U.S. sites Lilly plans to announce, will produce small molecule synthetic and peptide medicines.","length":398,"tagName":"p"},{"type":"text","content":"Importantly, the site will be among those that will manufacture orforglipron, Lilly's first oral, small molecule GLP-1 receptor agonist, which the company expects to submit to global regulatory agencies for obesity by the end of this year.","length":253,"tagName":"p"},{"type":"text","content":"Lilly will bring 450 high-value jobs to the area, including engineers, scientists, operations personnel and lab technicians. Construction, expected to begin in 2026, is anticipated to generate 3,000 construction jobs as the state-of-the-art facility is built. Completion is expected in 2032.","length":291,"tagName":"p"},{"type":"text","content":""Huntsville's track record of science and innovation, supported by advanced manufacturing expertise and a skilled workforce, makes Alabama an ideal location for Lilly to expand domestic manufacturing capacity for next‑generation medicines," said David A. Ricks, Lilly chair and CEO. "Today's investment continues the onshoring of active pharmaceutical ingredient (API) production, strengthening supply chain resilience and reliable access to medicines for patients in the U.S."","length":505,"tagName":"p"},{"type":"text","content":"Expanding Lilly's U.S. manufacturing presence in Alabama will boost the Huntsville economy. For every dollar Lilly invests there, it estimates up to four dollars in additional local economic activity. Also, for each manufacturing job created, ...